Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
A roundup of the first quarter's key oncology drug approvals and rejections.
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.
The company takes another project from Taris into phase 3 as it chases a $5bn market.